BioClinica Responds to Shareholder Letter (BIOC)
BioClinica™, Inc. (NASDAQ: BIOC) has issued the following statement:
The Board of Directors of BioClinica supports management, their extensive industry-specific knowledge, insight and business acumen. The Company has a strategic plan in place to enhance shareholder value, and we are executing upon that plan to build our business and strengthen and expand our suite of services while increasing our operational efficiency. We also have substantial and growing interest in our new eClinical offerings.
Management has always been open to discussions with our shareholders, and it is our intent to continue that dialogue in an effort to facilitate an understanding of our Company, its operations and our strategic growth plan. We are in receipt of a letter from one of our shareholders who has published that letter in the form of a press release. We want to assure our shareholders that the Company remains focused on enhancing long-term shareholder value and delivering high quality clinical trial services to our clients.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.